Several equities analysts have weighed in on the company. Scotiabank raised their price objective on BridgeBio Pharma from $55.00 to $57.00 and gave the company a "sector outperform" rating in a research note on Wednesday, August 6th. Raymond James Financial started coverage on shares of BridgeBio Pharma in a research report on Wednesday, July 30th. They set an "outperform" rating and a $56.00 price target on the stock. Truist Financial started coverage on shares of BridgeBio Pharma in a research report on Monday, July 21st. They issued a "buy" rating and a $66.00 price objective for the company. HC Wainwright increased their price objective on shares of BridgeBio Pharma from $56.00 to $70.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Finally, Wells Fargo & Company boosted their target price on BridgeBio Pharma from $67.00 to $76.00 and gave the stock an "overweight" rating in a research note on Monday, June 30th.